Tech Company Financing Transactions
Alamar Biosciences Funding Round
On 2/27/2024, Alamar Biosciences raised $128 million in Series C funding from Sands Capital Management and private investors.
Transaction Overview
Company Name
Announced On
2/27/2024
Transaction Type
Venture Equity
Amount
$128,000,000
Round
Series C
Investors
Sands Capital Management (Lead Investor) (Ian Ratcliffe)
Proceeds Purpose
The company intends to use the funds to grow the commercial and customer support teams, drive market adoption, and expand the product line.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
46421 Landing Pkwy.
Fremont, CA 94538
USA
Fremont, CA 94538
USA
Phone
Website
Email Address
Overview
We are creating the most sensitive proteomics platform that can profile thousands of proteins simultaneously from as little as one microliter of plasma. Our fully automated, high throughput platform will unmask new biomarkers for early detection and prevention of common diseases and advance human health.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Yuling Luo
Chief Financial Officer
Tod White
Chief Operating Officer
Steve Chen
Chief Technical Officer
Xiao-Jun Ma
VP - Engineering
Yiyuan Yin
Browse more venture capital transactions:
Prev: 2/27/2024: FamilyWell venture capital transaction
Next: 2/27/2024: Glean Technologies venture capital transaction
Share this article
Where The Data Comes From
We do our best to document tech company VC transactions. VC investment data records on this site come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs